Find in Library

Nowadays, antiplatelet drugs are still the routine medication in the acute phase and in secondary prevention of ischemic stroke. Although the clinical effect of classic antiplatelet drugs, such as aspirin and clopidogrel, has been recognized, some problems still exist, such as clopidogrel resistance and increased bleeding risk. Therefore, new antiplatelet drugs have been studied and are incorporated into the clinical use currently. Their different pharmacokinetic and pharmacodynamic properties are good additions to the classic antiplatelet therapy, so as to overcome the limitations of the latter. This article will summarize existing clinical evidences and highlight the main features of new antiplatelet drugs, as well as listing some challenges in the use of these therapies. <br />